[On the pharmacology of the beta-receptor blocker penbutolol (author's transl)]

Arzneimittelforschung. 1980;30(3):420-7.
[Article in German]

Abstract

1-tert.-Butylamino-3-(2-cyclopentylphenoxy)-propan-2-ol (penbutolol, Hoe 893d) is a beta-adrenergic blocking agent about 4 times more active than propranolol in vivo and in vitro. In comparison to propranolol it is characterized by a longer lasting activity. The antihypertensive effect of penbutolol in spontaneously hypertonic rats is more than 5 times stronger than that of propranolol. Penbutolol reduces basal plasma renin activity in the same dose range as does propranolol but is about 3 times stronger with respect to isoproterenol-induced increase of PRA. Penbutolol is 5 times more potent than propranolol inhibiting isoproterenol-stimulated phosphorylase activity in the isolated heart. In reserpine pretreated rats, penbutolol has a moderate intrinsic sympathomimetic activity (ISA). Penbutolol shows less unspecific actions -- such as negative inotropy or calcium antagonism -- than propranolol. Characteristic parameters of lung function (compliance and resistance) are less affected by penbutolol than propranolol in spite of the fact that penbutolol has a stronger beta-adrenergic blocking effect.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Calcium / antagonists & inhibitors
  • Cats
  • Dogs
  • Guinea Pigs
  • Hemodynamics / drug effects
  • Hypertension / physiopathology
  • In Vitro Techniques
  • Male
  • Muscle Contraction / drug effects
  • Penbutolol / pharmacology*
  • Penbutolol / toxicity
  • Phosphorylases / antagonists & inhibitors
  • Propanolamines / pharmacology*
  • Rats
  • Renin / blood
  • Respiration / drug effects
  • Species Specificity
  • Time Factors

Substances

  • Propanolamines
  • Penbutolol
  • Phosphorylases
  • Renin
  • Calcium